Risultati per: Approccio pre-rete e Cure Palliative di base
Questo è quello che abbiamo trovato per te
66 RCMIX MODEL BASED ON PRE-NEOADJUVANT THERAPY T2WI IMAGING CAN PREDICT THE T-STAGE DOWNSTAGING IN MRI-CT4 STAGE RECTAL CANCER PATIENTS
Mo1773 IS THERE A ROLE FOR BIOPSYING THE PRE-ANASTOMOTIC ILEUM IN CROHN'S PATIENTS: LONG-TERM OUTCOMES FOR PATIENTS WITH MICROSCOPIC INFLAMMATION IN THE NEOTERMINAL ILEUM
Sa1651 HEPATITIS C CURE WITH DIRECT ACTING ANTIVIRALS IN PERSONS WITH HIV LOWERS A METABOLITE-BASED PROGNOSTIC RISK SCORE BUT DOES NOT ALTER PLASMA METABOLITE PROFILES
Sa1606 SEVERE UNDERUTILIZATION OF PALLIATIVE/HOSPICE CARE AND DISCUSSION AMONG PATIENTS WITH CIRRHOSIS INCLUDING THOSE WITH DECOMPENSATION AND HCC: FINDINGS FROM A SINGLE-CENTER REAL-WORLD STUDY OF 15.876 PATIENTS
Tu1212 ABSENT MRS AUGMENTATION ON PRE-TRANSPLANT TESTING IS ASSOCIATED WITH DECREASED BOLUS CLEARANCE AFTER LUNG TRANSPLANT
EP49 PRE-OPERATIVE HIGH RESOLUTION ESOPHAGEAL MANOMETRY GUIDED PER ORAL ENDOSCOPIC GE JUNCTION MYOTOMY IN ALL TYPES OF ACHLASIA CARDIA HAS BETTER OUTCOMES -A RETROSPECTIVE ANALYSIS
EP105 IN A PRE-CLINICAL MICE MODEL OF COLITIS, THE CYTOKINES PROFILES ACROSS THE LARGE INTESTINE DIFFER IN A SEX-DEPENDENT MANNER.
Sa1579 OUTPATIENT PALLIATIVE CARE CO-MANAGEMENT FOR PATIENTS WITH CIRRHOSIS: A MIXED METHODS PILOT STUDY
Sa1537 FACTORS THAT IMPACT THE LIKELIHOOD OF PALLIATIVE CARE SPECIALTY INVOLVEMENT FOR HOSPITALIZED PATIENTS WITH CIRRHOSIS
834 PRE-OPERATIVE SERUM CREATININE PREDICTS MORBIDITY AND MORTALITY IN METABOLIC AND BARIATRIC SURGERY – AN MBSAQIP PROPENSITY SCORE MATCHED ANALYSIS
Medici, non si riducono le liste d'attesa tagliando le cure
Attesa per il decreto. Contestati i limiti alle prescrizioni
Implementation of a primary-tertiary shared care model to improve the detection of familial hypercholesterolaemia (FH): a mixed methods pre-post implementation study protocol
Introduction
Familial hypercholesterolaemia (FH) is an autosomal dominant inherited disorder of lipid metabolism and a preventable cause of premature cardiovascular disease. Current detection rates for this highly treatable condition are low. Early detection and management of FH can significantly reduce cardiac morbidity and mortality. This study aims to implement a primary-tertiary shared care model to improve detection rates for FH. The primary objective is to evaluate the implementation of a shared care model and support package for genetic testing of FH. This protocol describes the design and methods used to evaluate the implementation of the shared care model and support package to improve the detection of FH.
Methods and analysis
This mixed methods pre-post implementation study design will be used to evaluate increased detection rates for FH in the tertiary and primary care setting. The primary-tertiary shared care model will be implemented at NSW Health Pathology and Sydney Local Health District in NSW, Australia, over a 12-month period. Implementation of the shared care model will be evaluated using a modification of the implementation outcome taxonomy and will focus on the acceptability, evidence of delivery, appropriateness, feasibility, fidelity, implementation cost and timely initiation of the intervention. Quantitative pre-post and qualitative semistructured interview data will be collected. It is anticipated that data relating to at least 62 index patients will be collected over this period and a similar number obtained for the historical group for the quantitative data. We anticipate conducting approximately 20 interviews for the qualitative data.
Ethics and dissemination
Ethical approval has been granted by the ethics review committee (Royal Prince Alfred Hospital Zone) of the Sydney Local Health District (Protocol ID: X23-0239). Findings will be disseminated through peer-reviewed publications, conference presentations and an end-of-study research report to stakeholders.
HIV pre-exposure prophylaxis uptake, retention and adherence among female sex workers in sub-Saharan Africa: a systematic review
Objective
To evaluate oral pre-exposure prophylaxis (PrEP) uptake, retention and adherence among female sex workers (FSWs) receiving care through community and facility delivery models in sub-Saharan Africa (SSA).
Design
Systematic review and meta-analysis.
Data sources
We searched online databases (PubMed, MEDLINE, SCOPUS, EMBASE, Google Scholar, Cochrane Database of Systematic Reviews and Web of Science) between January 2012 and 3 April 2022.
Eligibility criteria for studies
Randomised controlled trials, cohort studies, cross-sectional studies and quasi-experimental studies with PrEP uptake, adherence and retention outcomes among FSWs in SSA.
Data extraction and synthesis
Seven coders extracted data. The framework of the Cochrane Consumers and Communication Review Group guided data synthesis. The Risk of Bias In Non-Randomized Studies of Interventions tool was used to evaluate the risk of bias. Meta-analysis was conducted using a random-effects model. A narrative synthesis was performed to analyse the primary outcomes of PrEP uptake, adherence and retention.
Results
Of 8538 records evaluated, 23 studies with 40 669 FSWs were included in this analysis. The pooled proportion of FSWs initiating PrEP was 70% (95% CI: 56% to 85%) in studies that reported on facility-based models and 49% (95% CI: 10% to 87%) in community-based models. At 6 months, the pooled proportion of FSWs retained was 66% (95% CI: 15% to 100%) for facility-based models and 83% (95% CI: 75% to 91%) for community-based models. Factors associated with increased PrEP uptake were visiting a sex worker programme (adjusted OR (aOR) 2.92; 95% CI: 1.91 to 4.46), having ≥10 clients per day (aOR 1.71; 95% CI: 1.06 to 2.76) and lack of access to free healthcare in government-run health clinics (relative risk: 1.16; 95% CI: 1.06 to 1.26).
Conclusions
A hybrid approach incorporating both facility-based strategies for increasing uptake and community-based strategies for improving retention and adherence may effectively improve PrEP coverage among FSWs.
PROSPERO registration number
CRD42020219363.
Danish Diabetes Birth Registry 2: a study protocol of a national prospective cohort study to monitor outcomes of pregnancies of women with pre-existing diabetes
Introduction
Despite technological developments and intensified care, pregnancies in women with pre-existing diabetes are still considered high-risk pregnancies. The rate of adverse outcomes in pregnancies affected by diabetes in Denmark is currently unknown, and there is a limited understanding of mechanisms contributing to this elevated risk. To address these gaps, the Danish Diabetes Birth Registry 2 (DDBR2) was established. The aims of this registry are to evaluate maternal and fetal-neonatal outcomes based on 5 years cohort data, and to identify pathophysiology and risk factors associated with short-term and long-term outcomes of pregnancies in women with pre-existing diabetes.
Methods and analysis
The DDBR2 registry is a nationwide 5-year prospective cohort with an inclusion period from February 2023 to February 2028 of pregnancies in women with all types of pre-existing diabetes and includes registry, clinical and questionnaire data and biological samples of mother–partner–child trios. Eligible families (parents age ≥18 years and sufficient proficiency in Danish or English) can participate by either (1) basic level data obtained from medical records (mother and child) and questionnaires (partner) or (2) basic level data and additional data which includes questionnaires (mother and partner) and blood samples (all). The primary maternal outcome is Hemoglobin A1c (HbA1c) levels at the end of pregnancy and the primary offspring endpoint is the birth weight SD score. The DDBR2 registry will be complemented by genetic, epigenetic and metabolomic data as well as a biobank for future research, and the cohort will be followed through data from national databases to illuminate possible mechanisms that link maternal diabetes and other parental factors to a possible increased risk of adverse long-term child outcomes.
Ethics and dissemination
Approval from the Ethical Committee is obtained (S-20220039). Findings will be sought published in international scientific journals and shared among the participating hospitals and policymakers.
Trial registration number
NCT05678543.
Stop al numero chiuso a Medicina, adottato il testo base in Senato
Marti, ‘massima convergenza’ in Commissione Istruzione al Senato